Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8235329 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 6 Pages |
Abstract
Patients with high-risk neuroblastoma in our series achieved excellent local control. Doses of 21-24 Gy to the primary tumor site appear to be adequate for local control for patients in the setting of minimal residual disease after induction chemotherapy and surgery. Patients with significant residual disease may benefit from radiation dose escalation, and this should be evaluated in a prospective clinical trial.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Heather G. M.D., R.B. M.D., Howard M. M.D., Mourad Ph.D., Natia M.D.,